*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Eli Lilly & Co's upcoming earnings report is poised to capture attention, particularly given the company's impressive market cap of $765.6 billion, which underscores its significant presence in the pharmaceutical industry. Analysts are closely watching the EPS estimate of $5.97 and revenue projection of $16.01 billion, but the whisper number of $6.70 suggests that market insiders are anticipating a stronger performance. This expectation may be fueled by Eli Lilly's strategic focus on innovative drug development and expansion into emerging markets, which have historically driven robust growth. As the earnings date approaches, investors will be keen to see if Eli Lilly can exceed these expectations and continue its trajectory of strong financial performance.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Website: https://www.lilly.com
Representative David Taylor recently purchased Amazon.com stock, with the value estimated between $23,023 and $345,000, according to a February 2, 2026 report. This transaction occurred on January 29,...
The New York Stock Exchange (NYSE) provides a daily pre-market update, highlighting mixed stock performance due to corporate earnings reports and a delayed January Jobs Report. AstraZeneca made a hist...
Revvity, Inc. (NYSE: RVTY) reported strong Q4 2025 earnings, surpassing expectations with adjusted EPS of $1.70. The company achieved 4% organic growth, driven by robust performance in its diagnostics...
Eli Lilly is expected to report strong fourth-quarter revenue, primarily driven by its weight-loss and diabetes drugs like Mounjaro and Zepbound, with analysts projecting $17.90 billion, exceeding man...
Jim Cramer highlighted Eli Lilly (NYSE: LLY) as a stock to watch, noting that its earnings typically aren't the main driver, but rather new reports on GLP-1 clinical trials. He suggested that upcoming...
Pfizer announced that its experimental obesity drug, PF’3944, achieved up to 12.3% weight loss in non-diabetic patients during a mid-stage trial. The drug, acquired through the Metsera deal, demonstra...